Critical appraisal:Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al 2005 1
From Cancer Guidelines Wiki
Risk of bias assessment: Randomised Controlled Trial (Cochrane risk of bias tool)
Random sequence generation
Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.
- The 65 169 women who were willing and eligible entered a 3-month run-in period using both placebo aspirin and placebo vitamin E to identify likely long-term compliers to pill taking. A total of 39 876 women remained willing and eligible, were compliant during run-in, and were randomized into the trial (19 934 to aspirin and 19 942 to placebo). Randomization used blocks of size 16 within 5-year age strata and took place from April 30, 1993, through January 24, 1996.
Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of or during, enrolment.
- Participants were sent an annual supply of monthly calendar packs containing active agents or placebo. Every 6 months for the first year, then every 12 months subsequently, participants were sent questionnaires seeking information on compliance, adverse effects, occurrence of relevant clinical end points, and risk factors. Study medications and end point ascertainment were continued in blinded fashion through the scheduled end of the trial on March 31, 2004.
Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.
- All participants were followed up for the occurrence of cancer or cardiovascular events. Following a report of cancer by questionnaire or death certificate, written consent for medical record review was requested from the participant, or next of kin if deceased, and medical records were obtained from hospitals or treating physicians. All relevant information was reviewed by the WHS Endpoints Committee composed of physicians blinded to treatment assignment.
Incomplete outcome data
Describe the completeness of outcome data for each main outcome, including attrition and exlusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.
- Attrition due to death (3.4%) and unknown vital status (0.6%). Data set is very large (over 39,000)
Selective outcome reporting
State how the possibility of selective outcome reporting was examined by the review authors and what was found.
- Outcomes clearly stated for the trial. Some data based on 'self-reported' diagnosis of colon polyp. As it was a blinded study, there shouldn't be an bias with this.
What was the risk of bias from selective outcome reporting? Assessments should be made for each main outcome (or class of outcomes).
Other sources of bias
- Maybe some potential for bias in the 3-month run-in period, but unlikely as someone with reaction to aspirin wouldn't take it anyway. Low level of bias.
Overall risk of bias
|Low risk of bias||Additional comments: Please replace this text and include any additional comments in regards to your risk of bias rating|
- Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005 Jul 6;294(1):47-55 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15998890.
- Assigned to
- Topic area
- Guidelines:Colorectal cancer/Primary Prevention
- Clinical question
- Form:Quality appraisal rct-cochrane
- CRC Indicidence
Section below only relevant for Cancer Council Project Officer